Caitong International Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Caitong International Asset Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29K	Buy	7,927 +7,665	+2,926%	+$46.6K	﹤0.01%	872
2026 Q1	$2.01K	Buy	262 +221	+539%	+$2.05K	﹤0.01%	1240
2025 Q4	$464	Buy	+41	New	+$417	﹤0.01%	1487
2025 Q2	–	Sell	-1,507	Closed	-$4.34K	–	2171
2025 Q1	$4.34K	Buy	1,507 +1,362	+939%	+$5K	﹤0.01%	1060
2024 Q4	$682	Buy	+145	New	+$535	﹤0.01%	1403

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caitong International Asset Management's FULC Position: Q2 2026 in Review

Caitong International Asset Management increased its Fulcrum Therapeutics (FULC) stake by 2,926% in Q2 2026, buying an estimated $46.6K and bringing the position to 7,927 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #872.

Caitong International Asset Management first reported a position in FULC in Q4 2024 and has held it in 5 quarters since. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Caitong International Asset Management held 7,927 shares of Fulcrum Therapeutics worth $29K as of Q2 2026.
Caitong International Asset Management bought 7,665 Fulcrum Therapeutics shares in Q2 2026, an estimated $46.6K.
Fulcrum Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #872 holding.
Caitong International Asset Management first reported a position in Fulcrum Therapeutics in Q4 2024 and has held it in 5 quarters since.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.